Work is underway to determine the efficacy and safety of oral baricitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, in patients with active chronic uveitis associated with JIA and in ANA-positive patients in whom methotrexate therapy remains ineffective or is poorly tolerated [85]. Here, BTG3 is linked to juvenile idiopathic arthritis.